1. Home
  2. EARN vs PBYI Comparison

EARN vs PBYI Comparison

Compare EARN & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • PBYI
  • Stock Information
  • Founded
  • EARN 2012
  • PBYI 2010
  • Country
  • EARN United States
  • PBYI United States
  • Employees
  • EARN N/A
  • PBYI N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • EARN Real Estate
  • PBYI Health Care
  • Exchange
  • EARN Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • EARN 189.7M
  • PBYI 263.4M
  • IPO Year
  • EARN 2013
  • PBYI N/A
  • Fundamental
  • Price
  • EARN $5.20
  • PBYI $5.46
  • Analyst Decision
  • EARN Buy
  • PBYI Strong Buy
  • Analyst Count
  • EARN 2
  • PBYI 1
  • Target Price
  • EARN $5.88
  • PBYI $7.00
  • AVG Volume (30 Days)
  • EARN 338.2K
  • PBYI 413.9K
  • Earning Date
  • EARN 11-19-2025
  • PBYI 11-06-2025
  • Dividend Yield
  • EARN 18.46%
  • PBYI N/A
  • EPS Growth
  • EARN N/A
  • PBYI 434.29
  • EPS
  • EARN N/A
  • PBYI 0.97
  • Revenue
  • EARN $35,893,000.00
  • PBYI $238,062,000.00
  • Revenue This Year
  • EARN N/A
  • PBYI N/A
  • Revenue Next Year
  • EARN $15.93
  • PBYI N/A
  • P/E Ratio
  • EARN N/A
  • PBYI $5.61
  • Revenue Growth
  • EARN 43.30
  • PBYI 8.63
  • 52 Week Low
  • EARN $4.33
  • PBYI $2.32
  • 52 Week High
  • EARN $6.99
  • PBYI $6.07
  • Technical
  • Relative Strength Index (RSI)
  • EARN 40.93
  • PBYI 60.64
  • Support Level
  • EARN $5.10
  • PBYI $5.14
  • Resistance Level
  • EARN $5.40
  • PBYI $5.61
  • Average True Range (ATR)
  • EARN 0.09
  • PBYI 0.26
  • MACD
  • EARN 0.03
  • PBYI -0.02
  • Stochastic Oscillator
  • EARN 48.73
  • PBYI 61.33

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: